Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 2/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2292608 | 0.83 | USP2 (0.52) | HPGDUSP2SMN1; SMN2DDB1CRBN | |
| SCHEMBL17629419 | 0.80 | USP2 (0.46) | HPGDUSP2SMN1; SMN2RORCDDB1 | |
| SCHEMBL43159 | 0.78 | NR1H2 (0.53) | HSD17B10HPGDUSP2SMN1; SMN2RORC | |
| SCHEMBL17611204 | 0.77 | USP2 (0.46) | USP2SMN1; SMN2NR1H2PTPN2PTPN1 | |
| SCHEMBL14043923 | 0.77 | USP2 (0.46) | HPGDUSP2SMN1; SMN2DDB1CRBN | |
| SCHEMBL1394242 | 0.75 | USP2 (0.44) | HPGDUSP2SMN1; SMN2DDB1CRBN | |
| SCHEMBL18668387 | 0.75 | USP2 (0.44) | HPGDUSP2SMN1; SMN2DDB1CRBN | |
| SCHEMBL18275033 | 0.75 | HPGD (0.53) | HSD17B10HPGDUSP2SMN1; SMN2GPR119 | |
| SCHEMBL89062 | 0.75 | NR1H2 (0.54) | HSD17B10HPGDUSP2SMN1; SMN2RORC | |
| SCHEMBL20220628 | 0.75 | NR1H2 (0.54) | HSD17B10HPGDUSP2SMN1; SMN2RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3353176-B1 | BICYCLIC COMPOUNDS AS ATX INHIBITORS | HOFFMANN LA ROCHE (CH) | 2022-01-19 | — | — | EP | disclosed |
| US-10800786-B2 | Bicyclic compounds as ATX inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20200087307-A1 | BICYCLIC COMPOUNDS AS ATX INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-03-19 | — | — | US | disclosed |
| US-20180312515-A1 | NEW BICYCLIC COMPOUNDS AS ATX INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2018-11-01 | — | — | US | disclosed |
| EP-3353176-A1 | BICYCLIC COMPOUNDS AS ATX INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2018-08-01 | — | — | EP | disclosed |
| WO-2017050792-A1 | BICYCLIC COMPOUNDS AS ATX INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10800786-B2 | Bicyclic compounds as ATX inhibitors | ATXN2, ATXN2L, ATXN10 | HSD17B10 4185/4885HPGD 4450/4885USP2 1731/4885 |
| US-20180312515-A1 | NEW BICYCLIC COMPOUNDS AS ATX INHIBITORS | ATXN2, ATXN2L, ATXN10 | HSD17B10 4235/4885HPGD 4536/4885USP2 1957/4885 |
| US-20200087307-A1 | BICYCLIC COMPOUNDS AS ATX INHIBITORS | ATXN2, ATXN2L, ATXN10 | HSD17B10 4185/4885HPGD 4450/4885USP2 1731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.